证券代码：600812 证券简称：华北制药 公告编号：临 2026-001 | 担保对象一 | 被担保人名称 | | | 华北制药河北华民药业有限责任公司 | | --- | --- | --- | --- | --- | | | 本次担保金额 | 34,800 | 万元 | | | | 实际为其提供的担保余额 | 69,300 | 万元 | | | | 是否在前期预计额度内 | √是 | □否 | □不适用：_________ | | | 本次担保是否有反担保 | □是 | √否 | □不适用：_________ | | 担保对象二 | 被担保人名称 | | | 华北制药金坦生物技术股份有限公司 | | | 本次担保金额 | 4,975 | 万元 | | | | 实际为其提供的担保余额 | 53,889.06 | 万元 | | | | 是否在前期预计额度内 | √是 | □否 | □不适用：_________ | | | 本次担保是否有反担保 | □是 | √否 | □不适用：_________ | | 担保对象三 | 被担保人名称 | | 华北制药集团爱诺有限公司 | | | | 本次担保金额 | 12, ...

来源：新浪财经-鹰眼工作室 国家药品监督管理局药品审评中心数据显示，2026年1月5日，Terumo Corporation, Kofu Factory的达依 泊汀α注射液申请已获受理，受理号为JTS2600001。 天眼查数据显示，华北制药金坦生物技术股份有限公司成立日期2002年04月02日，法定代表人程俊山， 企业类型为其他股份有限公司(非上市)，企业规模为中型，参保人数619，注册资本18505.1637万人民 币，实缴资本16398.9152万人民币，注册地址为石家庄高新区天山南大街106号。股东信息如下： 股东名称持股比例认缴出资额认缴出资日期首次持股日期华北制药股份有限公司98%16070.9369万元人 民币2014年3月17日2013年12月31日华北制药集团先泰药业有限公司2%327.9783万元人民币2014年3月 17日2013年12月31日 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的 ...

Core Viewpoint - The company has announced a "Quality Improvement and Efficiency Enhancement Action Plan" aimed at promoting high-quality development and enhancing investment value, particularly for small and medium-sized investors [1][3]. Group 1: Business Focus and Strategy - The company focuses on its core business of pharmaceutical product research, production, and sales, emphasizing quality and human health as its mission [1]. - The company aims to enhance operational quality by improving existing business areas and exploring new growth through innovation and collaboration [2][5]. Group 2: Shareholder Returns - The company has established a three-year shareholder return plan (2023-2025), prioritizing cash profit distribution, with a commitment to distribute at least 30% of the average annual distributable profit over the three years [3][4]. - Cumulative cash dividends over the last three accounting years amounted to 68.63 million yuan, exceeding the planned return requirements [3]. Group 3: Technological Innovation - The company has invested approximately 3.7 billion yuan in R&D since 2022, with an annual average R&D investment increase of 108.78% from 2019 to 2021 [5]. - Significant breakthroughs in technology include the approval of a new drug and multiple product launches, demonstrating the company's commitment to innovation [5][6]. Group 4: Investor Relations Management - The company emphasizes effective communication with investors through various channels, ensuring transparency and timely updates on company developments [7][8]. - Regular performance briefings and investor education activities are conducted to enhance investor understanding and protect their rights [7]. Group 5: Corporate Governance - The company adheres to relevant laws and regulations, continuously improving its governance structure and internal control systems to enhance operational standards [9][10]. - A new committee structure has been established to strengthen decision-making and oversight, ensuring fair treatment of all shareholders [10][11].

Core Viewpoint - North China Pharmaceutical has announced a "Quality Improvement and Efficiency Enhancement Return" action plan aimed at enhancing operational quality, shareholder returns, and fostering technological innovation [1] Group 1: Action Plan Highlights - The company will focus on its core business to improve operational quality [1] - Emphasis will be placed on shareholder returns, with a commitment to distribute no less than 30% of annual distributable profits as cash dividends [1] - The plan includes strengthening investor relations management to enhance value transmission [1] Group 2: Financial Commitments - Over the past three years, the company has distributed a total of 68.6292 million yuan in dividends [1] - Cumulative investment in research and development over three years amounts to approximately 3.7 billion yuan [1] Group 3: Governance and Management - The company aims to improve governance standards and operational compliance [1] - There will be a focus on managing the "key minority" to solidify responsibility in performance [1]

华北制药股份有限公司 关于"提质增效重回报"行动方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为深入贯彻党的二十大和中央金融工作会议精神，落实国务院《关于 进一步提高上市公司质量的意见》要求，积极响应上海证券交易所《关于 开展沪市公司"提质增效重回报"专项行动的倡议》，推动公司高质量发 展和投资价值提升，保护投资者尤其是中小投资者合法权益，华北制药股 份有限公司（以下简称"公司"）结合公司战略规划及自身实际经营情况， 制定了"提质增效重回报"行动方案。本次行动方案已于 2025 年 12 月 29 日经公司第十一届董事会第二十六次会议审议通过，具体方案如下： 一、聚焦主责主业，提升经营质量 公司主要从事医药产品的研发、生产和销售等业务，产品涉及化学制 药、现代生物技术药物、维生素及健康消费品、生物农兽药等领域。公司 始终秉持"人类健康至上，质量永远第一"的企业宗旨，以"一切为了人 类健康"为企业使命，努力打造国内领先、国际一流的医药健康产业集团， 建设美丽新华药。 近年来，公司以党的建设为统领，"稳中求进"为总基 ...

证券代码：600812 证券简称：华北制药 编号：临 2025-065 表决结果：同意 10 票； 反对 0 票； 弃权 0 票。 特此公告。 一、董事会会议召开情况 华北制药股份有限公司（以下简称"公司"）第十一届董事会第二十 六次会议于 2025 年 12 月 26 日向全体董事及公司高级管理人员以电子邮件 形式发出会议通知，以通讯方式于 2025 年 12 月 29 日召开。本次会议应出 席董事 10 名，实际出席董事 10 名。会议的召集、召开和表决程序符合《公 司法》等法律、行政法规、部门规章、规范性文件和《公司章程》的规定。 二、董事会会议审议情况 会议审议并以书面表决方式通过了以下议案： （一）审议通过《关于制定"提质增效重回报"行动方案的议案》 具体内容详见公司同日刊登于《上海证券报》《中国证券报》和上海 证券交易所网站（www.sse.com.cn）的《关于"提质增效重回报"行动方 案的公告》。 华北制药股份有限公司 第十一届董事会第二十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 华北制 ...

Core Viewpoint - The report highlights the trends and statistics in the Chinese chemical pharmaceutical industry, indicating a slight decline in production while maintaining overall growth in the sector [1]. Industry Summary - As of October 2025, the production of chemical pharmaceutical raw materials in China reached 313,000 tons, showing a year-on-year decrease of 1.6% [1]. - From January to October 2025, the cumulative production of chemical pharmaceutical raw materials was 3,049,000 tons, reflecting a cumulative growth of 1.3% [1]. - The report is based on data from the National Bureau of Statistics and is compiled by Zhiyan Consulting, a leading industry consulting firm in China [1]. Company Summary - Listed companies in the sector include Heng Rui Medicine, East China Pharmaceutical, Lizhu Group, Baiyunshan, North China Pharmaceutical, Haizheng Pharmaceutical, Fosun Pharmaceutical, Kelun Pharmaceutical, Enhua Pharmaceutical, and Xianju Pharmaceutical [1].

Summary of Key Points Core Viewpoint - As of December 18, the margin financing and securities lending balance in the Shanghai and Shenzhen markets decreased to 24,916.5 billion yuan, reflecting a reduction of 34.69 billion yuan from the previous trading day [1]. Group 1: Market Overview - The financing balance stands at 24,748.41 billion yuan, down by 33.13 billion yuan compared to the previous trading day [1]. - The Shanghai market's margin balance is 12,666.44 billion yuan, decreasing by 43.7 billion yuan, while the Shenzhen market's balance is 12,250.06 billion yuan, increasing by 9.01 billion yuan [1]. Group 2: Stock Performance - A total of 1,604 stocks experienced net buying of margin funds, with 60 stocks having net buying amounts exceeding 10% of their total trading volume [3]. - The top three stocks by net buying ratio are: - Hotway Co., Ltd. (24.35%) - Xinhongye (23.16%) - Saitex New Materials (23.13%) [4][5]. Group 3: Significant Net Buying Stocks - There are 29 stocks with net buying amounts exceeding 100 million yuan, with the top three being: - Xinyi Sheng (609 million yuan) - China Ping An (516 million yuan) - China Satellite (278 million yuan) [7].

证券代码：600812 证券简称：华北制药 公告编号：临2025-063 华北制药股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2025年12月15日 (二)股东大会召开的地点：石家庄市和平东路388号公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ■ (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议采取现场投票与网络投票相结合的方式召开，由王立鑫先生主持会议；本次会议的召集、召开 及表决方式符合《公司法》《公司章程》及《公司股东大会议事规则》等法律、法规和其他规范性文件 的有关规定。 (五)公司董事、监事和董事会秘书的出席情况 1.公司在任董事9人，出席8人，董事王秀军先生因工作原因未能出席会议； 2.公司在任监事5人，出席1人，监事高文赞先生、杨立军先生、张锁庆先生和李凡先生因工作原因未能 出席会议； 3.董 ...

Group 1 - The company announced the approval of the election of the vice chairman of the board during the 25th meeting of the 11th board of directors [2] - The company also approved the adjustment of the members of the Strategic (Investment Decision) and Sustainable Development Committee of the board [2]